Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026)
Phathom Pharmaceuticals' (PHAT) quarterly Cash from Investing Activities came in at -$61000.0 in Q1 2026, down 238.89% year-on-year from $43920.0 in Q1 2025, and up 29.89% on a QoQ basis from -$87000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Cash from Investing Activities data on file, last reported at -$61000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 238.89% year-over-year to -$61000.0 in Q1 2026; TTM through Mar 2026 was -$272000.0, a 140.71% decrease from a year earlier, with the FY2025 full-year figure at -$229000.0, down 69.63% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$61000.0, up from -$87000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for PHAT reached as high as -$5000.0 in Q4 2024 and fell as low as -$939000.0 in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$182352.9 across 5 years, with a median of -$67000.0 in 2022.
- Across the five-year window, Cash from Investing Activities jumped 98.95% in 2024 and slumped 1640.0% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$412000.0 in 2022, then dropped by 15.29% to -$475000.0 in 2023, then soared by 98.95% to -$5000.0 in 2024, then slumped by 1640.0% to -$87000.0 in 2025, then climbed by 29.89% to -$61000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$61000.0 in Q1 2026, -$87000.0 in Q4 2025, and -$27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Phathom Pharmaceuticals | 981.33 Mn | 797.56 Mn | 46.31 Mn | -61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61,000.00 |
| Mar 31, 2026 | -61,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Dec 31, 2023 | -475,000.00 |
| Dec 31, 2023 | -475,000.00 |